HUTCHMED (China) (HCM) Stock Overview
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
HCM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeHUTCHMED (China) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.91 |
| 52 Week High | UK£2.92 |
| 52 Week Low | UK£1.91 |
| Beta | 0.38 |
| 1 Month Change | -13.18% |
| 3 Month Change | -12.79% |
| 1 Year Change | -10.75% |
| 3 Year Change | -15.86% |
| 5 Year Change | -49.07% |
| Change since IPO | 662.48% |
Recent News & Updates
HCM: Late Stage Oncology Trials And Guidance Will Drive Future Reassessment
Analysts have adjusted their price target on HUTCHMED (China) slightly, linking the change to updated assumptions for revenue growth and profit margins, together with a higher future P/E of 58.40x. What's in the News HUTCHMED issued 2026 guidance for Oncology/Immunology consolidated revenue in a range of US$330m to US$450m, providing a management view of expected business activity for the year (corporate guidance).HCM: Advancing Late Stage Oncology Pipeline Will Drive Future Reassessment
Analysts have nudged their fair value estimate for HUTCHMED (China) higher to £5.62 from £5.34, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that have slightly adjusted their overall outlook. What's in the News Initiated a registrational Phase III trial of BTK inhibitor HMPL-760 with R-GemOx in relapsed or refractory diffuse large B-cell lymphoma in China, targeting about 240 patients and using progression free survival and overall survival as primary outcomes (Product-Related Announcement).Recent updates
HCM: Late Stage Oncology Trials And Guidance Will Drive Future Reassessment
Analysts have adjusted their price target on HUTCHMED (China) slightly, linking the change to updated assumptions for revenue growth and profit margins, together with a higher future P/E of 58.40x. What's in the News HUTCHMED issued 2026 guidance for Oncology/Immunology consolidated revenue in a range of US$330m to US$450m, providing a management view of expected business activity for the year (corporate guidance).HCM: Advancing Late Stage Oncology Pipeline Will Drive Future Reassessment
Analysts have nudged their fair value estimate for HUTCHMED (China) higher to £5.62 from £5.34, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that have slightly adjusted their overall outlook. What's in the News Initiated a registrational Phase III trial of BTK inhibitor HMPL-760 with R-GemOx in relapsed or refractory diffuse large B-cell lymphoma in China, targeting about 240 patients and using progression free survival and overall survival as primary outcomes (Product-Related Announcement).
HCM: Late-Stage Pipeline Progress Will Drive Future Re-Rating Potential
Analysts have trimmed their price target on HUTCHMED (China) to £3.51 from £3.62, reflecting updated assumptions that combine higher expected revenue growth with a lower profit margin profile and a richer forward P/E multiple. What's in the News Management issued consolidated earnings guidance for 2026, with Oncology/Immunology revenue expected in a range of US$330 million to US$450 million, giving investors a clearer view of the medium term revenue outlook (Corporate guidance).HCM: Phase III Oncology Progress Will Drive Reassessment Of Future Upside
Analysts have trimmed their price target on HUTCHMED (China) to about US$5.34 from roughly US$5.50, citing updated assumptions that include higher forecast revenue growth and profit margins, along with a lower implied future P/E multiple. What's in the News The Phase III SACHI trial of savolitinib (ORPATHYS) plus osimertinib (TAGRISSO) in EGFR mutation positive NSCLC with MET amplification was published in The Lancet.What You Can Learn From HUTCHMED (China) Limited's (LON:HCM) P/S
When you see that almost half of the companies in the Pharmaceuticals industry in the United Kingdom have...Is HUTCHMED (China) (LON:HCM) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...China And Japan Oncology Markets Will Broaden Opportunity Amidst Headwinds
HUTCHMED (China)’s valuation outlook has improved with a notable drop in its future P/E ratio from 35.13x to 26.14x while net profit margin held steady, resulting in no change to the consensus analyst price target, which remains £3.62. What's in the News Dr. Weiguo Su takes medical leave as CEO; CFO Johnny Cheng appointed Acting CEO while retaining CFO role.Revenues Tell The Story For HUTCHMED (China) Limited (LON:HCM) As Its Stock Soars 31%
HUTCHMED (China) Limited ( LON:HCM ) shareholders would be excited to see that the share price has had a great month...Late-stage Approvals And Global Expansion Will Unlock Demand
Late-stage pipeline progress, geographic expansion, and international partnerships position the company for strong, sustainable revenue and margin growth.After Leaping 26% HUTCHMED (China) Limited (LON:HCM) Shares Are Not Flying Under The Radar
HUTCHMED (China) Limited ( LON:HCM ) shareholders would be excited to see that the share price has had a great month...HUTCHMED (China) Limited's (LON:HCM) Stock Retreats 25% But Earnings Haven't Escaped The Attention Of Investors
HUTCHMED (China) Limited ( LON:HCM ) shareholders that were waiting for something to happen have been dealt a blow with...Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...HUTCHMED (China) Limited's (LON:HCM) 27% Jump Shows Its Popularity With Investors
HUTCHMED (China) Limited ( LON:HCM ) shares have had a really impressive month, gaining 27% after a shaky period...Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report
It's been a good week for HUTCHMED (China) Limited ( LON:HCM ) shareholders, because the company has just released its...HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable
With a median price-to-sales (or "P/S") ratio of close to 3.3x in the Pharmaceuticals industry in the United Kingdom...We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce
HUTCHMED (China) Limited ( LON:HCM ) shareholders are no doubt pleased to see that the share price has bounced 31% in...The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts
One thing we could say about the analysts on HUTCHMED (China) Limited ( LON:HCM ) - they aren't optimistic, having just...Shareholder Returns
| HCM | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -2.1% | -1.9% | -0.8% |
| 1Y | -10.7% | 22.9% | 19.7% |
Return vs Industry: HCM underperformed the UK Pharmaceuticals industry which returned 22.9% over the past year.
Return vs Market: HCM underperformed the UK Market which returned 19.7% over the past year.
Price Volatility
| HCM volatility | |
|---|---|
| HCM Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in GB Market | 11.6% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: HCM has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: HCM's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,796 | Johnny Cheng | www.hutch-med.com |
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML).
HUTCHMED (China) Limited Fundamentals Summary
| HCM fundamental statistics | |
|---|---|
| Market cap | UK£1.68b |
| Earnings (TTM) | UK£336.25m |
| Revenue (TTM) | UK£403.67m |
Is HCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HCM income statement (TTM) | |
|---|---|
| Revenue | US$548.51m |
| Cost of Revenue | US$484.64m |
| Gross Profit | US$63.87m |
| Other Expenses | -US$393.04m |
| Earnings | US$456.91m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.53 |
| Gross Margin | 11.64% |
| Net Profit Margin | 83.30% |
| Debt/Equity Ratio | 7.4% |
How did HCM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 18:41 |
| End of Day Share Price | 2026/05/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HUTCHMED (China) Limited is covered by 52 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| John Newman | Canaccord Genuity |
| Adam McCarter | Cavendish |